COMPASS Pathways PLC Sustainability Reports
COMPASS Pathways plc is a clinical-stage biotechnology company developing psychedelic therapies to address serious mental health conditions. Its primary asset is COMP360, a synthetic psilocybin treatment under evaluation for treatment-resistant depression, PTSD, and anorexia nervosa.
Sector: Manufacturing
Country: United Kingdom
Exchange: Nasdaq
LEI: 213800N7CUZIC6QSTZ31
FIGI: BBG00X0VY3F8
4 reports from 2022 to 2025
